Before you go, get my Ultimate Midlife Health Guide

The 8 most common health challenges at midlife, and what you can do about each one.
Free, and sent straight to your inbox.

TL; DR – A randomized controlled trial published December 30, 2025 showed that a personalized, precision medicine approach to cognitive decline was 7x more effective than Leqembi and 4x more effective than Kisunla — the FDA-approved Alzheimer’s drugs. Unlike those drugs, this approach actually improved cognitive function rather than just slowing decline, with no dangerous side effects like brain swelling or microbleeds. Instead, patients got healthier overall. I’m trained in this protocol (the Bredesen ReCODE approach) and use it both for treatment and prevention. If you’re a professional woman in midlife experiencing brain fog or cognitive changes — or if you have a family history of dementia — this matters for you.
If you’ve been told that cognitive decline is inevitable — that the best you can hope for is to slow it down — I need you to read this.
On December 30, 2025, a landmark study was published that validates what precision medicine practitioners have been seeing for years: cognitive improvement is possible. Not just slowing decline. Actual reversal.
This randomized controlled trial compared a personalized, precision medicine approach to standard-of-care treatment in patients with mild cognitive impairment or early dementia. The results:
7x the effect size of Leqembi (lecanemab)
4x the effect size of Kisunla (donanemab)
These comparisons are based on effect size calculations for overall cognitive function outcomes across trials. Effect size measures how much of a real-world difference an intervention makes — and by this measure, the precision medicine approach dramatically outperformed the FDA-approved drugs that have been making headlines.
But here’s what matters even more: the precision medicine approach did something those drugs don’t do. It actually improved cognitive function rather than simply slowing decline.
Seventy-three patients with mild cognitive impairment or early dementia were randomly assigned to either a personalized precision medicine protocol or standard-of-care treatment. Over nine months, researchers tracked their cognitive function, symptoms, brain health, and overall metabolic markers.
The precision medicine group showed statistically significant improvements in:
• Broad neurocognitive functioning (the overall measure of brain performance)
• Composite memory — both verbal and visual
• Executive function (planning, decision-making, complex thinking)
• Processing speed
• Cognitive symptom severity
• Alzheimer’s disease symptom severity
The standard-of-care group? They declined — exactly as expected with conventional treatment.
One critical note: this study included patients with MoCA scores of 18 or higher — meaning mild cognitive impairment or early-stage dementia. Patients with more advanced cognitive decline (MoCA below 18) were excluded. This underscores a crucial point: early intervention matters. The earlier you address the contributors to cognitive decline, the more opportunity there is for improvement.
Here’s what makes this even more significant: the precision medicine approach had none of the dangerous side effects associated with anti-amyloid drugs like Leqembi and Kisunla.
Those FDA-approved drugs carry risks of ARIA — amyloid-related imaging abnormalities — which can include brain swelling and microhemorrhages. Some patients have died. The drugs require regular MRI monitoring and careful patient selection.
The precision medicine approach? Instead of side effects, patients experienced improved overall health:
• Lower blood pressure
• Reduced body mass index
• Better blood sugar control (lower HbA1c)
• Improved insulin sensitivity
• Healthier lipid profiles
• Better methylation status (lower homocysteine)
This isn’t a treatment that trades cognitive benefits for other health risks. It’s an approach that improves the whole person.
For decades, Alzheimer’s research has been dominated by the “amyloid hypothesis” — the idea that if we could just clear the amyloid plaques from the brain, we’d solve the disease. Billions of dollars and countless clinical trials later, the best we’ve achieved with that approach is modestly slowing decline.
The problem? Cognitive decline isn’t caused by one thing. It’s a complex network insufficiency with many contributing factors:
• Insulin resistance and metabolic dysfunction
• Chronic inflammation
• Hormonal imbalances
• Nutrient deficiencies
• Chronic infections
• Toxin exposure
• Sleep disorders
• Vascular dysfunction
• Gut dysbiosis
A single drug targeting a single mechanism can’t address all of these. A personalized approach that identifies your specific contributors and addresses each one? That’s a different story entirely.
This wasn’t a pill. It was a comprehensive, personalized program that addressed multiple systems simultaneously:
Patients were evaluated for markers of inflammation, chronic infection, gut health, immune dysfunction, insulin resistance, vascular disease, sleep disorders, hormone status, nutrient levels, and toxin exposure. Genetic testing identified individual vulnerabilities. This isn’t standard care — it’s detective work.
A plant-rich, mildly ketogenic diet high in fiber and healthy fats, low in glycemic load. Patients monitored blood ketones, targeting 1.0-4.0 mM beta-hydroxybutyrate — providing the brain with an alternative fuel source that bypasses impaired glucose metabolism.
At least 45 minutes of aerobic exercise six days per week, plus strength training twice weekly, including high-intensity interval training. Exercise increases BDNF — brain-derived neurotrophic factor — which supports neuroplasticity and neuron survival.
Seven to eight hours of quality sleep, with home sleep studies to identify and treat sleep apnea or upper airway resistance syndrome. Poor sleep accelerates cognitive decline; optimizing it protects the brain’s overnight cleaning system.
For those with suboptimal hormonal status, bioidentical hormone replacement was provided. This included sex hormones, neurosteroids like DHEA and pregnenolone, and thyroid optimization. Hormones are neuroprotective — and their decline in midlife has real cognitive consequences.
Structured cognitive training using BrainHQ, at least 15 minutes daily. The brain training group improved by 25 percentile points on assessments — demonstrating that the brain remains plastic and trainable even in early cognitive decline.
Based on individual testing results: treatment of identified infections, detoxification protocols for those with toxin exposure, gut healing protocols, anti-inflammatory support, and addressing any other contributors identified in the comprehensive workup.
This study focused on people who already had mild cognitive impairment or early dementia. But here’s what’s critical to understand: the same factors that drive cognitive decline at 70 are often present — and addressable — at 45.
Insulin resistance doesn’t suddenly appear when you notice memory problems. Chronic inflammation builds over years. Hormonal changes in perimenopause and menopause affect the brain decades before dementia might develop.
If a precision medicine approach can reverse cognitive decline in people who already have it, we don’t have to imagine what it could do for prevention. We already do that.
I use the same protocol — the same comprehensive testing, the same targeted interventions, the same attention to hormones, inflammation, toxins, and metabolic health — with patients who want to prevent cognitive decline, not just treat it after it’s started.
I see women in their 40s and 50s who want to protect their brains before problems start — especially those with a family history of Alzheimer’s or dementia. They’re not waiting for symptoms. They’re taking action now because they understand that the brain changes of dementia begin years, even decades, before the first memory lapses.
The best time to address the contributors to cognitive decline is before you have symptoms. The second-best time is now.
Women make up nearly two-thirds of Alzheimer’s patients. This isn’t just because we live longer — research increasingly points to the role of estrogen in brain protection and the vulnerability that comes with its decline during menopause.
Perimenopause brings unique brain and heart vulnerabilities. Hot flashes aren’t just uncomfortable — they’re associated with changes in brain white matter and increased cardiovascular risk. The loss of estrogen makes everything else less efficient: our metabolism slows, our ability to detoxify diminishes, inflammation increases, and insulin sensitivity decreases.
This is why I take a broad approach that addresses everything — not just hormones in isolation, but the entire interconnected system that affects brain health. Hormone optimization, yes, but also metabolic health, inflammation, detoxification, sleep, stress, and all the other factors that compound during this transition.
The study explicitly included bioidentical hormone replacement for perimenopausal and menopausal women as part of the protocol. This aligns with growing evidence that the menopausal transition represents a critical window for brain health intervention.
For professional women experiencing brain fog, memory issues, and cognitive changes in their 40s and 50s — this is not “just stress” or “just perimenopause” in the sense of something to simply endure. These are signals worth investigating and addressing.
There’s a phenomenon happening in workplaces that no one is naming.
Women are leaving senior leadership at unprecedented rates in their 40s and 50s. The conventional explanation is burnout, caregiving demands, or lack of flexibility. But there’s a hidden variable that’s being missed: perimenopause is affecting women’s brains at the exact moment they reach peak career responsibility.
Brain fog in a board meeting. Struggling to find words during a presentation. Fatigue that no amount of sleep seems to fix. Anxiety that appeared out of nowhere. These aren’t character flaws or signs that you can’t handle the job. They’re symptoms of a hormonal transition that affects cognitive function — and they’re addressable.
I call this the “perimenopause broken rung” — a hidden barrier that causes high-performing women to step back, scale down, or leave leadership entirely, not because they’ve lost ambition but because they’re fighting a biological battle no one is acknowledging.
This study matters for these women. It demonstrates that cognitive function can be improved — not through willpower or pushing through, but through identifying and addressing the underlying contributors to brain dysfunction.
You don’t have to choose between your career and your brain health. You don’t have to accept cognitive decline as the price of being a woman in midlife. And you don’t have to wait until you have a diagnosis to take action.
This study won’t change medicine overnight. It’s a preprint — not yet peer-reviewed. The sample size was relatively small. The approach is complex and requires practitioners trained in this methodology.
But here’s what it demonstrates: the conventional wisdom that cognitive decline is irreversible is wrong. The approach of targeting a single mechanism with a single drug is fundamentally limited. And a personalized, comprehensive approach that addresses the multiple contributors to brain dysfunction can achieve what monotherapy cannot.
For those of us practicing this approach, this study is validation. For patients and families facing cognitive decline, it’s hope grounded in evidence.
I’m trained in the Bredesen protocol — the precision medicine approach validated in this trial. Through my Resilient Brain program, I work with patients to identify and address the specific factors contributing to their cognitive concerns — whether they’re seeking treatment for existing symptoms or prevention before symptoms develop.
What I see in practice aligns with what this study shows: when you stop treating the brain as separate from the body, when you address the underlying metabolic, hormonal, inflammatory, and toxic contributors to dysfunction, cognitive function can improve.
This isn’t about waiting until you have a diagnosis. It’s about understanding that brain health is whole-body health, that the factors affecting cognition are identifiable and modifiable, and that taking action in your 40s and 50s can change your trajectory for decades to come.
If you’re experiencing cognitive changes — brain fog, word-finding difficulties, memory issues, decreased processing speed — don’t accept “it’s just aging” as an answer. These symptoms have causes, and those causes are often addressable.
If you have a family history of Alzheimer’s or dementia, prevention is not passive. The factors that contribute to cognitive decline can be identified and modified years before symptoms appear.
If you’re a professional woman in midlife navigating perimenopause or menopause, know that what’s happening to your brain is real, it’s not “just hormones” in the dismissive sense, and there are evidence-based approaches to protect and optimize your cognitive function.
The science is clear: cognitive decline is not inevitable, and for those willing to take a comprehensive, personalized approach, reversal is possible.
If you’re a professional woman experiencing cognitive changes — or if you want to protect your brain before problems start — book a discovery call to discuss whether this approach is right for you.
Reference: Toups K, Tanio C, Hathaway A, et al. Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled Trial. Preprints. 2025. doi:10.20944/preprints202512.2694.v1
Functional Medicine Practitioner & Wellness Expert
Dr. Manna Semby, ND, FMCP-M, MSCP, is a naturopathic and functional medicine doctor based in San Diego, California. She is the only doctor in the San Diego area who is both a Menopause Society Certified Practitioner and certified in the ReCODE 2.0 Protocol for preventing and reversing Alzheimer’s disease and dementia. She is also is a MoCA certified administrator. With over ten years in medicine, Dr. Manna has helped many women reverse early stages of cognitive decline through comprehensive brain, bone, metabolic, and midlife hormone medical care. She draws on years of clinical training and ongoing professional development to translate complex medical insights into practical, real-world precision medicine guidance.
Every program starts with one conversation: a 40-minute Initial Call with me to hear your concerns and see whether one of our programs is right for you.